Genomic Profile of Breast Cancer: Cost-effectiveness Analysis from the Spanish National Healthcare System Perspective

Publication Name: Expert Review of Pharmacoeconmics & Outcomes Research

Author(s): Miguel Ángel Seguí, Carlos Crespo, Javier Cortés, Ana Lluch, Max Brosa, Virginia Becerra, Sebastián Matias Chiavenna, and Alfredo Gracia

Background: Cost–effectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. … Continued

MammaPrint® translating research into a diagnostic test, Molecular Diagnostics, The Key Driver in Personalized Cancer Medicine

Publication Name: CMC Contrast, Denmark) & Henrik Winther (Dako, Denmark) Pan Stanford Publihing

Author(s): Annuska M Glas, Leonie Delahaye and Oscar Krijgsman

Gene expression profiles that provide clinical utility have been developed in the last decade. However, only a handful are currently available for broad clinical use through commercial enterprises. Once a test does enter the clinical setting it is imperative to … Continued

The future of diagnostic microarrays; bridging the gap between bench and bedside.

Publication Name: Bioanalysis

Author(s): Roepman, Paul

During the last two decades, an increasing number of microarray studies have identified gene-expression profiles that link disease characteristics to patient outcome. However, despite improvements in technology and the clinical relevance of the identified profiles, only a handful of microarray … Continued

Gene Expression profiling: Decoding breast cancer.

Publication Name: Surgical Oncology

Author(s): deSnoo F , Bender R, Glas G and Rutgers E

Gene expression assays that are used in daily clinical practice for treating early breast cancer patients have been introduced in the clinic only recently. This review discusses the development of these arrays, summarizes the validation of those that are commercially … Continued

MammaPrint the 70-gene signature – another milestone in personalized medical care for breast cancer patients.

Publication Name: Expert Review, Diagnostic Profile

Author(s): EA Slodkowska and JS Ross

The MammaPrint™ assay (Agendia BV, The Netherlands) is the first fully commercialized microarray-based multigene assay designed to individualize treatment for patients with breast cancer. MammaPrint, the first assay to be cleared at the 510(k) level by the US FDA’s new in … Continued

Mammary gland biology and breast cancer. Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression

Publication Name: EMBO Reports

Author(s): Sharon F McGee, Fiona Lanigan, Emer Gilligan,and Bernd Groner

Introduction:  As a model system for biological investigations, the mouse mammary gland is as versatile as the Drosophilaeye. This comparison does not reflect any ignorance of comparative anatomy, but rather it highlights the multitude of possibilities that the mammary gland … Continued

Microarray analysis and tumor classification.

Publication Name: New England Journal of Medicine

Author(s): J. Quackenbush, Ph.D.

DNA microarray analysis was first described in the mid-1990s as a means to probe the expression of thousands of genes simultaneously(1,2) and was quickly adopted by the research community for the study of a wide range of biologic processes. Most … Continued

On the Toxicity of Chemotherapy for Breast Cancer – —the Need for Vigilance

Publication Name: Journal of the National Cancer Institute- Editorial

Author(s): John K. Erban , Joseph Lau

A study published in The Journal of the National Cancer Institute, found that advanced chemotherapy put patients at far greater risks of harm than adverse effect reports from clinical trial data reveal. “Researchers mined insurance claims for 3,526 women who … Continued

Molecular profiling of breast cancer: clinical implications

Publication Name: British Journal of Cancer

Author(s): S Cleator, A Ashworth

Breast cancers are routinely subcategorised on the basis of clinical stage, cellular morphology and immunohistochemical analysis of a small number of markers. The recent development of gene expression microarray and related technologies provides an opportunity to perform more detailed profiling … Continued